Molecular Oncology Causes of Cancer and Targets for Treatment 1st Edition by Gelmann EP ISBN 0521876621 9780521876629

Molecular Oncology Causes of Cancer and Targets for Treatment 1st Edition by Gelmann EP – Ebook PDF Instant Download/Delivery: 0521876621, 9780521876629
Full download Molecular Oncology Causes of Cancer and Targets for Treatment 1st Edition after payment

Product details:

ISBN 10: 0521876621 
ISBN 13: 9780521876629
Author: Gelmann EP

Molecular Oncology Causes of Cancer and Targets for Treatment 1st Table of contents:

Part 1.1 Analytical techniques: analysis of DNA

1. Cancer genome sequencing

2. Genome-wide association studies of cancer predisposition

3. Comparative genomic hybridization

4. Chromosome analysis: molecular cytogenetic approaches

5. DNA methylation

Part 1.2 Analytical techniques: analysis of RNA
6. The application of high-throughput analyses to cancer diagnosis and prognosis
7. Cancer proteomics
8. Tyrosine kinome profiling: oncogenic mutations and therapeutic targeting in cancer
9. In situ techniques for protein analysis in tumor tissue

Part 2.1 Molecular pathways underlying carcinogenesis: signal transduction
10. HER
11. The insulin–insulin-like growth-factor receptor family as a therapeutic target in oncology
12. TGF-β signaling in stem cells and tumorigenesis
13. Platelet-derived growth factor
14. FMS-related tyrosine kinase 3
15. ALK: Anaplastic lymphoma kinase
16. The FGF signaling axis in prostate tumorigenesis
17. Hepatocyte growth factor/Met signaling in cancer
18. PI3K
19. Intra-cellular tyrosine kinase
20. WNT signaling in neoplasia
21. Ras
22. BRAF mutations in human cancer: biologic and therapeutic implications
23. Aurora kinases in cancer: an opportunity for targeted therapy
24. 14-3-3 proteins in cancer
25. STAT signaling as a molecular target for cancer therapy
26. The MYC oncogene family in human cancer
27. Jun proteins and AP-1 in tumorigenesis
28. Forkhead box proteins: the tuning forks in cancer development and treatment
29. NF-κB and cancer

Part 2.2 Molecular pathways underlying carcinogenesis: apoptosis
30. Apoptosis: the extrinsic pathway
31. Apoptosis: the intrinsic pathway

Part 2.3 Molecular pathways underlying carcinogenesis: nuclear receptors
32. Androgens and the androgen receptor (AR)
33. Emerging roles of peroxisome proliferator-activated receptor gamma in cancer

Part 2.4 Molecular pathways underlying carcinogenesis: DNA repair
34. The ATM-mediated DNA-damage response
35. Werner syndrome: association of premature aging and cancer predisposition
36. Hereditary disorders of DNA repair and DNA damage tolerance that predispose to neoplastic transformation
37. Telomerase: target for cancer treatment

Part 2.5 Molecular pathways underlying carcinogenesis: cell cycle
38. Cell cycle: mechanisms of control and dysregulation in cancer
39. DNA-damage-induced apoptosis

Part 2.6 Molecular pathways underlying carcinogenesis: other pathways
40. The ubiquitin/proteasome pathway in neoplasia
41. Small silencing non-coding RNAs: cancer connections and significance

Part 3.1 Molecular pathology: carcinomas
42. Head and neck cancer
43. Lung cancer
44. Esophageal cancer
45. Gastric cancer
46. Small-bowel tumors: molecular mechanisms and targeted therapy
47. Colon and rectal cancer
48. Pancreatic cancer
49. Hepatocellular carcinoma
50. Renal-cell carcinomas
51. Bladder cancer
52. Prostate cancer
53. Targeted therapies in breast cancer
54. Molecular targets for epithelial ovarian cancer
55. Testicular cancer: germ-cell tumors (GCTs)
56. Cervical cancer

Part 3.2 Molecular pathology: cancers of the nervous system
57. Brain tumors
58. Mechanisms of pituitary tumorigenesis
59. Molecular oncology of neuroblastoma
60. Neurofibromatosis type I

Part 3.3 Molecular pathology: cancers of the skin
61. Squamous-cell carcinoma
62. Molecular oncology of basal cell carcinomas
63. Melanoma

Part 3.4 Molecular pathology: endocrine cancers
64. Oncogenic events and therapeutic targets in thyroid cancer
65. The parathyroid glands
66. Multiple endocrine neoplasia type 2 (MEN2)

Part 3.5 Molecular pathology: adult sarcomas
67. Sarcomas

Part 3.6 Molecular pathology: lymphoma and leukemia
68. Molecular pathology of lymphoma
69. The molecular basis of acute myeloid leukemia
70. Molecular oncology of acute promyelocytic leukemia (APL)
71. Acute lymphoblastic leukemia (ALL)
72. B-cell chronic lymphocytic leukemia
73. Chronic myeloid leukemia: imatinib and next-generation ABL inhibitors
74. Multiple myeloma
75. EMS: the 8p11 myeloproliferative syndrome
76. JAK2 and myeloproliferative neoplasms

Part 3.7 Molecular pathology: pediatric solid tumors
77. Pediatric solid tumors: embryonal cell oncogenesis

Part 4 Pharmacologic targeting of oncogenic pathways
78. Oncology drug discovery for biologics: antibody development strategies and considerations
79. Targeting the EGFR family of receptor tyrosine kinases
80. Therapeutic approaches with antibodies to cell-surface receptors
81. Signal transduction in tumor angiogenesis
82. Tyrosine-kinase inhibitors in oncology
83. Anti-estrogens and selective estrogen-receptor modulators
84. Therapeutic applications of anti-sense mechanisms for the treatment of cancer
85. Induction of apoptosis
86. DNA-methylation inhibitors
87. Histone deacetylase inhibitor
88. Drug resistance: as complex and diverse as the disease itself
89. Molecular profiling and therapeutic decision-making: the promise of personalized medicine
90. DNA repair inhibition in anti-cancer therapeutics

People also search for Molecular Oncology Causes of Cancer and Targets for Treatment 1st:

Tags: Gelmann EP, Molecular Oncology, Cancer